Ignite Creation Date:
2025-12-24 @ 10:35 PM
Ignite Modification Date:
2025-12-31 @ 1:22 PM
Study NCT ID:
NCT05073835
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-12-06
First Post:
2021-09-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Semaglutide 2.4 mg in Patients With Poor Weight-loss
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009765', 'term': 'Obesity'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D024821', 'term': 'Metabolic Syndrome'}], 'ancestors': [{'id': 'D050177', 'term': 'Overweight'}, {'id': 'D044343', 'term': 'Overnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D001835', 'term': 'Body Weight'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D007333', 'term': 'Insulin Resistance'}, {'id': 'D006946', 'term': 'Hyperinsulinism'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000591245', 'term': 'semaglutide'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR'], 'maskingDescription': 'double blinded: both participants and study doctors will be blind to group allocation'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Phase 3b, double-blinded, randomised, parallel group trial'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 70}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2022-11-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-12', 'completionDateStruct': {'date': '2025-09', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-12-05', 'studyFirstSubmitDate': '2021-09-15', 'studyFirstSubmitQcDate': '2021-09-28', 'lastUpdatePostDateStruct': {'date': '2024-12-06', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-10-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-03', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Weight loss', 'timeFrame': '68 weeks', 'description': 'Percentage of total weight loss'}], 'secondaryOutcomes': [{'measure': 'body weight reduction ≥10%', 'timeFrame': '68 weeks', 'description': 'To compare the percentage of participants receiving subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo who after 68 weeks achieve a body weight reduction ≥10%'}, {'measure': 'body weight reduction ≥15%', 'timeFrame': '68 weeks', 'description': 'To compare the percentage of participants receiving subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo who after 68 weeks achieve a body weight reduction ≥15%'}, {'measure': 'body weight reduction ≥20%', 'timeFrame': '68 weeks', 'description': 'To compare the percentage of participants receiving subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo who after 68 weeks achieve a body weight reduction ≥20%'}, {'measure': 'Change in circulating HbA1c levels', 'timeFrame': '68 weeks', 'description': 'The effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon HbA1c'}, {'measure': 'Change in circulating HbA1c levels in participants with pre-diabetes at baseline', 'timeFrame': '68 weeks', 'description': 'The effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon HbA1c in participants with pre-diabetes at baseline'}, {'measure': 'Change in circulating HbA1c levels in participants with T2D at baseline', 'timeFrame': '68 weeks', 'description': 'The effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon HbA1c in participants with diabetes at baseline'}, {'measure': 'Systolic and diastolic BP', 'timeFrame': '68 weeks', 'description': 'The effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon BP'}, {'measure': 'Systolic and diastolic BP in participants with pre-existing hypertension', 'timeFrame': '68 weeks', 'description': 'The effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon BP in participants with pre-existing hypertension'}, {'measure': 'pharmacological agents required for the management of hypertension', 'timeFrame': '68 weeks', 'description': 'The number of pharmacological agents required for the management of hypertension in participants with pre-existing hypertension'}, {'measure': 'Change in circulating lipids', 'timeFrame': '68 weeks', 'description': 'To compare the effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon circulating lipids'}, {'measure': 'Change in circulating HsCRP and inflammatory cytokines', 'timeFrame': '68 weeks', 'description': 'To compare the effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon inflammatory markers'}, {'measure': 'Changes in food craving scores assessed through power of food questionnaire', 'timeFrame': '68 weeks', 'description': 'To compare the effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon food cravings'}, {'measure': 'Changes in HRQoL', 'timeFrame': '68 weeks', 'description': 'To compare the effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon HRQoL'}, {'measure': 'GLP-1 levels', 'timeFrame': '68 weeks', 'description': 'To investigate the relationship between fasted and meal-stimulated active GLP-1 levels at baseline and %WL at 68 weeks'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['obesity', 'diabetes', 'semaglutide'], 'conditions': ['Obesity', 'Diabetes', 'Metabolic Syndrome']}, 'descriptionModule': {'briefSummary': 'A double-blinded, randomised, placebo-controlled trial of semaglutide 3.0 mg/ml in patients with poor weight-loss following bariatric surgery. The primary aim of this trial is to determine whether, and the extent to which, 68 weeks of subcutaneous semaglutide 3.0 mg/ml causes greater percentage weight loss (%WL), reduction in adiposity, improvement in metabolic and inflammatory indices and health-related quality of life (HRQoL) than placebo, in patients with poor weight loss following gastric bypass or sleeve gastrectomy.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Patients, ≥1 year primary GB or primary SG, with poor weight-loss (\\<20% WL) that is not caused by either a surgical or psychological problem.\n2. Adults, 18-65 years inclusive.\n3. Females of childbearing potential and female partners of male participants must be willing to use highly effective method of contraception (hormonal or barrier method of birth control; abstinence) (Appendix 2) from the time consent is signed until 2 months after treatment discontinuation.\n4. Females of childbearing potential must have a negative pregnancy test within 7 days prior to randomisation. NOTE: Subjects are considered not of child bearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.\n5. A self-reported ≤5 % variation in body weight over preceding 3 months.\n6. Fluent in English and able to understand and complete questionnaires.\n7. Participants capable to provide written informed consent and comply with the trial protocol.\n\nExclusion Criteria:\n\n1. Bariatric surgical procedure other than GB and SG, or revision bariatric surgery of any operation type.\n2. Personal history of type I diabetes or type II diabetes mellitus currently treated with insulin.\n3. Concomitant use of GLP-1R agonist or DPPIV-inhibitors.\n4. Female who is pregnant, breast-feeding, or intends to become pregnant.\n5. Current participation in other clinical intervention trial.\n6. History of suicidal attempt in the previous 5 years or untreated severe depression or mental health condition assessed by direct questioning.\n7. Symptomatic gallstone disease\n8. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg).\n9. Renal impairment measured as glomerular infiltration rate (eGFR \\<15 ml/min 1.73 m2\n10. Known or suspected hypersensitivity to semaglutide or any of the excipients involved in their formulation.\n11. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.\n12. History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.\n13. Personal history of acute pancreatitis 180 days before screening or chronic pancreatitis.\n14. Uncontrolled thyroid disease.\n15. History of stroke, unstable angina, acute coronary syndrome, congestive heart failure New York Heart Association class III-IV within the preceding 12 months.\n16. Untreated clinically significant arrhythmias.\n17. Diabetic gastroparesis.\n18. Concomitant usage of medications that cause weight gain or weight loss.\n19. Known or suspected abuse of alcohol or recreational drugs.\n20. Severe hepatic impairment diagnosed via liver function blood tests and clinical evaluation\n21. Any additional factor, which in the investigator's opinion, might jeopardise the subject's safety or compliance with the trial protocol."}, 'identificationModule': {'nctId': 'NCT05073835', 'acronym': 'BARI-STEP', 'briefTitle': 'Semaglutide 2.4 mg in Patients With Poor Weight-loss', 'organization': {'class': 'OTHER', 'fullName': 'University College, London'}, 'officialTitle': 'BARI-STEP:A Double-blinded, Randomised, Placebo-controlled Trial of Semaglutide 2.4 mg in Patients With Poor Weight-loss Following Bariatric Surgery.', 'orgStudyIdInfo': {'id': '142522'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Intervention', 'description': 'Semaglutide 2.4mg/week subcutaneous injection for 68 weeks. The treatment includes an initial 16-week escalation phase followed by 52 weeks of treatment at study dose, i.e., 2.4mg/week.', 'interventionNames': ['Drug: Semaglutide 3 mg']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Control', 'description': 'Placebo administration, once weekly, subcutaneous injection.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Semaglutide 3 mg', 'type': 'DRUG', 'description': 'Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).', 'armGroupLabels': ['Intervention']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo', 'armGroupLabels': ['Control']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'WC1E 6JF', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Janine Makaronids', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University College, London', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}